Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359641 | 0.83 | SIGMAR1 (0.46) | PDK1 | |
| SCHEMBL38651897 | 0.79 | MLYCD (0.50) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL14266578 | 0.76 | MLYCD (0.43) | SCN9AGPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL2376808 | 0.74 | CD274 (0.42) | — | |
| SCHEMBL5065542 | 0.74 | PDK1 (0.43) | HRH3PDK1 | |
| SCHEMBL30239652 | 0.73 | HRH3 (0.50) | HRH3HRH2HRH1SLC6A4SCN7A | |
| SCHEMBL6155172 | 0.73 | OPRM1 (0.44) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6650593 | 0.72 | CHRNB2 (0.42) | GPR119AR | |
| SCHEMBL7282122 | 0.72 | PGR (0.39) | SCN9AGPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL3868314 | 0.71 | CHRNB2 (0.41) | GPR119AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | HRH3 39/4885MCHR1 1952/4885HRH2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.